NewAmsterdam Pharma (NAMS) stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.

Decades of market research reveals that the best-performing stocks tend to have an RS Rating north of 80 at the beginning of a new price run.

Here Are 3 Keys For Successful Stock Investing

Is NewAmsterdam Pharma Stock A Buy?

NewAmsterdam Pharma stock broke out earlier, but has fallen back below the prior 26.35 entry from a consolidation. If a stock you're watching climbs above a buy point then retreats 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new base and breakout. Also understand that the latest pattern is a later-stage base, and such bases are more prone to failure.

The biotech company posted 0% earnings growth in its most recent report. Revenue increased 942%.

NewAmsterdam Pharma stock holds the No. 30 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Corcept Therapeutics (CORT) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks